APO Research
Talk to an analyst

APO RESEARCH · REPORT

PARP Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PARP Inhibitors for Cancer Industry Growth and Trends Forecast to 2032

2 January 202699 pages

Choose your research edition.

Industry ResearchPARP Inhibitors for Cancer Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal PARP Inhibitors for Cancer Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal PARP Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PARP Inhibitors for Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PARP Inhibitors for Cancer Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global PARP Inhibitors for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PARP Inhibitors for Cancer include Merck & Co, Pfizer, AstraZeneca, Tesaro and Clovis Oncology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PARP Inhibitors for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PARP Inhibitors for Cancer market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PARP Inhibitors for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PARP Inhibitors for Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PARP Inhibitors for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PARP Inhibitors for Cancer Market by Company

Merck & Co

Pfizer

AstraZeneca

Tesaro

Clovis Oncology

PARP Inhibitors for Cancer Segment by Type

Lynparza

Rubraca

Zejula

Talzenna

Other

PARP Inhibitors for Cancer Segment by Application

Ovarian Cancer

Breast Cancer

Other

PARP Inhibitors for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PARP Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PARP Inhibitors for Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PARP Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Lynparza Table 2. Major Company of Rubraca Table 3. Major Company of Zejula Table 4. Major Company of Talzenna Table 5. Major Company of Other Table 6. Global PARP Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 8. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Type (2021-2026) Table 9. Global PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 10. Global PARP Inhibitors for Cancer Sales Market Share in Value by Type (2021-2026) Table 11. Global PARP Inhibitors for Cancer Price by Type (2021-2026) & (US$/Unit) Table 12. Global PARP Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 13. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Type (2027-2032) Table 14. Global PARP Inhibitors for Cancer Sales by Type (2027-2032) & (US$ Million) Table 15. Global PARP Inhibitors for Cancer Sales Market Share in Value by Type (2027-2032) Table 16. Global PARP Inhibitors for Cancer Price by Type (2027-2032) & (US$/Unit) Table 17. North America PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 18. North America PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 19. Europe PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 20. Europe PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 24. Latin America PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa PARP Inhibitors for Cancer Sales by Type (2021-2026) & (US$ Million) Table 27. PARP Inhibitors for Cancer Industry Trends Table 28. PARP Inhibitors for Cancer Industry Drivers Table 29. PARP Inhibitors for Cancer Industry Opportunities and Challenges Table 30. PARP Inhibitors for Cancer Industry Restraints Table 31. Global PARP Inhibitors for Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global PARP Inhibitors for Cancer Revenue Market Share by Company (2021-2026) Table 33. Global PARP Inhibitors for Cancer Sales by Company (2021-2026) & (K Units) Table 34. Global PARP Inhibitors for Cancer Sales Share by Company (2021-2026) Table 35. Global PARP Inhibitors for Cancer Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global PARP Inhibitors for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global PARP Inhibitors for Cancer Major Company Production Sites and Headquarters Table 38. Global PARP Inhibitors for Cancer Company, Product Type & Application Table 39. Global PARP Inhibitors for Cancer Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global PARP Inhibitors for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global PARP Inhibitors for Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global PARP Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 44. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Region (2021-2026) Table 45. Global PARP Inhibitors for Cancer Sales by Region (2021-2026) & (US$ Million) Table 46. Global PARP Inhibitors for Cancer Sales Market Share in Value by Region (2021-2026) Table 47. Global PARP Inhibitors for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global PARP Inhibitors for Cancer Sales by Region (2027-2032) & (K Units) Table 49. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Region (2027-2032) Table 50. Global PARP Inhibitors for Cancer Sales by Region (2027-2032) & (US$ Million) Table 51. Global PARP Inhibitors for Cancer Sales Market Share in Value by Region (2027-2032) Table 52. Global PARP Inhibitors for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global PARP Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 55. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Application (2021-2026) Table 56. Global PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 57. Global PARP Inhibitors for Cancer Sales Market Share in Value by Application (2021-2026) Table 58. Global PARP Inhibitors for Cancer Price by Application (2021-2026) & (US$/Unit) Table 59. Global PARP Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 60. Global PARP Inhibitors for Cancer Sales Market Share in Volume by Application (2027-2032) Table 61. Global PARP Inhibitors for Cancer Sales by Application (2027-2032) & (US$ Million) Table 62. Global PARP Inhibitors for Cancer Sales Market Share in Value by Application (2027-2032) Table 63. Global PARP Inhibitors for Cancer Price by Application (2027-2032) & (US$/Unit) Table 64. North America PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 65. North America PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 66. Europe PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 67. Europe PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 71. Latin America PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa PARP Inhibitors for Cancer Sales by Application (2021-2026) & (US$ Million) Table 74. Merck & Co Company Information Table 75. Merck & Co Business Overview Table 76. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Merck & Co PARP Inhibitors for Cancer Product Portfolio Table 78. Merck & Co Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Pfizer PARP Inhibitors for Cancer Product Portfolio Table 83. Pfizer Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. AstraZeneca PARP Inhibitors for Cancer Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Tesaro Company Information Table 90. Tesaro Business Overview Table 91. Tesaro PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Tesaro PARP Inhibitors for Cancer Product Portfolio Table 93. Tesaro Recent Development Table 94. Clovis Oncology Company Information Table 95. Clovis Oncology Business Overview Table 96. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Clovis Oncology PARP Inhibitors for Cancer Product Portfolio Table 98. Clovis Oncology Recent Development Table 99. North America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 100. North America PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 101. North America PARP Inhibitors for Cancer Sales Market Share by Country (2021-2026) Table 102. North America PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 103. North America PARP Inhibitors for Cancer Sales Market Share Forecast by Country (2027-2032) Table 104. North America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 105. North America PARP Inhibitors for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 106. North America PARP Inhibitors for Cancer Market Share by Country (2021-2026) Table 107. North America PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 108. North America PARP Inhibitors for Cancer Market Share Forecast by Country (2027-2032) Table 109. Europe PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 110. Europe PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 111. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2021-2026) Table 112. Europe PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 113. Europe PARP Inhibitors for Cancer Sales Market Share Forecast by Country (2027-2032) Table 114. Europe PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. Europe PARP Inhibitors for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 116. Europe PARP Inhibitors for Cancer Market Share by Country (2021-2026) Table 117. Europe PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. Europe PARP Inhibitors for Cancer Market Share Forecast by Country (2027-2032) Table 119. Asia-Pacific PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. Asia-Pacific PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 121. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share by Country (2021-2026) Table 122. Asia-Pacific PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 123. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share Forecast by Country (2027-2032) Table 124. Asia-Pacific PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Asia-Pacific PARP Inhibitors for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 126. Asia-Pacific PARP Inhibitors for Cancer Market Share by Country (2021-2026) Table 127. Asia-Pacific PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Asia-Pacific PARP Inhibitors for Cancer Market Share Forecast by Country (2027-2032) Table 129. Latin America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Latin America PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 131. Latin America PARP Inhibitors for Cancer Sales Market Share by Country (2021-2026) Table 132. Latin America PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 133. Latin America PARP Inhibitors for Cancer Sales Market Share Forecast by Country (2027-2032) Table 134. Latin America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Latin America PARP Inhibitors for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 136. Latin America PARP Inhibitors for Cancer Market Share by Country (2021-2026) Table 137. Latin America PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Latin America PARP Inhibitors for Cancer Market Share Forecast by Country (2027-2032) Table 139. Middle East and Africa PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 141. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share by Country (2021-2026) Table 142. Middle East and Africa PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032) & (K Units) Table 143. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share Forecast by Country (2027-2032) Table 144. Middle East and Africa PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Middle East and Africa PARP Inhibitors for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa PARP Inhibitors for Cancer Market Share by Country (2021-2026) Table 147. Middle East and Africa PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Middle East and Africa PARP Inhibitors for Cancer Market Share Forecast by Country (2027-2032) Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. PARP Inhibitors for Cancer Distributors List Table 152. PARP Inhibitors for Cancer Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. PARP Inhibitors for Cancer Image Figure 2. Global PARP Inhibitors for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PARP Inhibitors for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global PARP Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 5. Lynparza Image Figure 6. Global Lynparza Sales YoY Growth (2021-2032) & (K Units) Figure 7. Rubraca Image Figure 8. Global Rubraca Sales YoY Growth (2021-2032) & (K Units) Figure 9. Zejula Image Figure 10. Global Zejula Sales YoY Growth (2021-2032) & (K Units) Figure 11. Talzenna Image Figure 12. Global Talzenna Sales YoY Growth (2021-2032) & (K Units) Figure 13. Other Image Figure 14. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global PARP Inhibitors for Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global PARP Inhibitors for Cancer Market Share by Type 2025 VS 2032 Figure 17. North America PARP Inhibitors for Cancer Sales Market Share in Volume by Type in 2025 Figure 18. North America PARP Inhibitors for Cancer Sales Market Share in Value by Type in 2025 Figure 19. Europe PARP Inhibitors for Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Europe PARP Inhibitors for Cancer Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share in Value by Type in 2025 Figure 23. Latin America PARP Inhibitors for Cancer Sales Market Share in Volume by Type in 2025 Figure 24. Latin America PARP Inhibitors for Cancer Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 PARP Inhibitors for Cancer Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Ovarian Cancer Image Figure 30. Global Ovarian Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Breast Cancer Image Figure 32. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global PARP Inhibitors for Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global PARP Inhibitors for Cancer Market Share by Application 2025 VS 2032 Figure 37. North America PARP Inhibitors for Cancer Sales Market Share in Volume by Application in 2025 Figure 38. North America PARP Inhibitors for Cancer Sales Market Share in Value by Application in 2025 Figure 39. Europe PARP Inhibitors for Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Europe PARP Inhibitors for Cancer Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific PARP Inhibitors for Cancer Sales Market Share in Value by Application in 2025 Figure 43. Latin America PARP Inhibitors for Cancer Sales Market Share in Volume by Application in 2025 Figure 44. Latin America PARP Inhibitors for Cancer Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa PARP Inhibitors for Cancer Sales Market Share in Value by Application in 2025 Figure 47. North America PARP Inhibitors for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America PARP Inhibitors for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America PARP Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America PARP Inhibitors for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe PARP Inhibitors for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe PARP Inhibitors for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe PARP Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe PARP Inhibitors for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific PARP Inhibitors for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific PARP Inhibitors for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific PARP Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific PARP Inhibitors for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America PARP Inhibitors for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America PARP Inhibitors for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America PARP Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America PARP Inhibitors for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa PARP Inhibitors for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa PARP Inhibitors for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa PARP Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa PARP Inhibitors for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. PARP Inhibitors for Cancer Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. PARP Inhibitors for Cancer Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Rubraca
  • Zejula
  • Talzenna
  • Other
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Merck & Co
  • Pfizer
  • AstraZeneca
  • Tesaro
  • Clovis Oncology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PARP Inhibitors for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PARP Inhibitors for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PARP Inhibitors for Cancer Market by Type
  6. 1.3.1 Lynparza
  7. 1.3.2 Rubraca
  8. 1.3.3 Zejula
  9. 1.3.4 Talzenna
  10. 1.3.5 Other
  11. 1.4 Global PARP Inhibitors for Cancer Market Size by Type
  12. 1.4.1 Global PARP Inhibitors for Cancer Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global PARP Inhibitors for Cancer Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global PARP Inhibitors for Cancer Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America PARP Inhibitors for Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe PARP Inhibitors for Cancer Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific PARP Inhibitors for Cancer Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America PARP Inhibitors for Cancer Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa PARP Inhibitors for Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PARP Inhibitors for Cancer Industry Trends
  2. 2.2 PARP Inhibitors for Cancer Industry Drivers
  3. 2.3 PARP Inhibitors for Cancer Industry Opportunities and Challenges
  4. 2.4 PARP Inhibitors for Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PARP Inhibitors for Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by PARP Inhibitors for Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by PARP Inhibitors for Cancer Price (2021-2026)
  4. 3.4 Global PARP Inhibitors for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PARP Inhibitors for Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global PARP Inhibitors for Cancer Company, Product Type & Application
  7. 3.7 Global PARP Inhibitors for Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PARP Inhibitors for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PARP Inhibitors for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PARP Inhibitors for Cancer Tier 1, Tier 2, and Tier 3
4 PARP Inhibitors for Cancer Regional Status and Outlook
  1. 4.1 Global PARP Inhibitors for Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PARP Inhibitors for Cancer Historic Market Size by Region
  3. 4.2.1 Global PARP Inhibitors for Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PARP Inhibitors for Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PARP Inhibitors for Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PARP Inhibitors for Cancer Forecasted Market Size by Region
  7. 4.3.1 Global PARP Inhibitors for Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PARP Inhibitors for Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PARP Inhibitors for Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PARP Inhibitors for Cancer by Application
  1. 5.1 PARP Inhibitors for Cancer Market by Application
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global PARP Inhibitors for Cancer Market Size by Application
  6. 5.2.1 Global PARP Inhibitors for Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global PARP Inhibitors for Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global PARP Inhibitors for Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America PARP Inhibitors for Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe PARP Inhibitors for Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific PARP Inhibitors for Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America PARP Inhibitors for Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa PARP Inhibitors for Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck & Co
  2. 6.1.1 Merck & Co Company Information
  3. 6.1.2 Merck & Co Business Overview
  4. 6.1.3 Merck & Co PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck & Co PARP Inhibitors for Cancer Product Portfolio
  6. 6.1.5 Merck & Co Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer PARP Inhibitors for Cancer Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca PARP Inhibitors for Cancer Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Tesaro
  20. 6.4.1 Tesaro Company Information
  21. 6.4.2 Tesaro Business Overview
  22. 6.4.3 Tesaro PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Tesaro PARP Inhibitors for Cancer Product Portfolio
  24. 6.4.5 Tesaro Recent Developments
  25. 6.5 Clovis Oncology
  26. 6.5.1 Clovis Oncology Company Information
  27. 6.5.2 Clovis Oncology Business Overview
  28. 6.5.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Clovis Oncology PARP Inhibitors for Cancer Product Portfolio
  30. 6.5.5 Clovis Oncology Recent Developments
7 North America by Country
  1. 7.1 North America PARP Inhibitors for Cancer Sales by Country
  2. 7.1.1 North America PARP Inhibitors for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PARP Inhibitors for Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America PARP Inhibitors for Cancer Market Size by Country
  6. 7.2.1 North America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PARP Inhibitors for Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PARP Inhibitors for Cancer Sales by Country
  2. 8.1.1 Europe PARP Inhibitors for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PARP Inhibitors for Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PARP Inhibitors for Cancer Market Size by Country
  6. 8.2.1 Europe PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PARP Inhibitors for Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PARP Inhibitors for Cancer Sales by Country
  2. 9.1.1 Asia-Pacific PARP Inhibitors for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PARP Inhibitors for Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PARP Inhibitors for Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PARP Inhibitors for Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PARP Inhibitors for Cancer Sales by Country
  2. 10.1.1 South America PARP Inhibitors for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PARP Inhibitors for Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America PARP Inhibitors for Cancer Market Size by Country
  6. 10.2.1 South America PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PARP Inhibitors for Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PARP Inhibitors for Cancer Sales by Country
  2. 11.1.1 Middle East and Africa PARP Inhibitors for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PARP Inhibitors for Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PARP Inhibitors for Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa PARP Inhibitors for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PARP Inhibitors for Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PARP Inhibitors for Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PARP Inhibitors for Cancer Value Chain Analysis
  2. 12.1.1 PARP Inhibitors for Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PARP Inhibitors for Cancer Production Mode & Process
  7. 12.2 PARP Inhibitors for Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PARP Inhibitors for Cancer Distributors
  10. 12.2.3 PARP Inhibitors for Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst